One ton of peptides from Asia entered Brazil through an airport while ANVISA maintains restrictions on the legal compounding of these inputs, according to information from the sectoral portal ICTQ.
The scenario highlights a regulatory contradiction in the national pharmaceutical market: while the importation of Asian peptides continues to be registered by Brazilian customs, the regulatory agency has implemented measures that limit the use of these inputs in compounding pharmacies.
According to ICTQ, the entry of this significant quantity of peptides through the airport occurs in parallel with ANVISA's guidance against legal compounding of these compounds. The issue raises questions about the coherence between import policies and the restrictions imposed on their processing and use in the country.
Peptides are molecules of growing interest in the pharmaceutical market and the supplementation industry, with varied applications across different segments. The importation of inputs of this nature depends on customs and sanitary regulations, while their use in compounding pharmacies is subject to ANVISA standards.
The sectoral portal provided no details about the specific origin of the peptides, companies involved, or the final destination of the shipment. No information was disclosed about possible regulatory actions regarding the cargo.
The situation reflects ongoing tensions between different actors in the Brazilian pharmaceutical sector regarding the regulatory framework for pharmaceutical inputs, particularly in the peptides segment, where definitions about the permissibility of compounding remain subject to regulatory debate.
